Annual Net Income
-$19.03 M
-$974.70 K-5.40%
31 December 2023
Summary:
Inhibikase Therapeutics annual net profit is currently -$19.03 million, with the most recent change of -$974.70 thousand (-5.40%) on 31 December 2023. During the last 3 years, it has fallen by -$16.18 million (-568.17%). IKT annual net income is now -784.04% below its all-time high of -$2.15 million, reached on 31 December 2018.IKT Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$5.78 M
-$818.50 K-16.50%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly net profit is currently -$5.78 million, with the most recent change of -$818.50 thousand (-16.50%) on 30 September 2024. Over the past year, it has dropped by -$1.18 million (-25.74%). IKT quarterly net income is now -1269.54% below its all-time high of -$421.90 thousand, reached on 30 June 2020.IKT Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$19.57 M
-$1.18 M-6.43%
30 September 2024
Summary:
Inhibikase Therapeutics TTM net profit is currently -$19.57 million, with the most recent change of -$1.18 million (-6.43%) on 30 September 2024. Over the past year, it has dropped by -$435.10 thousand (-2.27%). IKT TTM net income is now -1026.83% below its all-time high of -$1.74 million, reached on 31 March 2019.IKT TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.4% | -25.7% | -2.3% |
| 3 y3 years | -568.2% | -29.2% | -78.6% |
| 5 y5 years | -784.0% | -376.6% | -269.6% |
IKT Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -568.2% | at low | -38.3% | at low | -78.6% | at low |
| 5 y | 5 years | -784.0% | at low | -1269.5% | at low | -845.2% | at low |
| alltime | all time | -784.0% | at low | -1269.5% | at low | -1026.8% | at low |
Inhibikase Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.78 M(+16.5%) | -$19.57 M(+6.4%) |
| June 2024 | - | -$4.96 M(+6.7%) | -$18.38 M(-4.3%) |
| Mar 2024 | - | -$4.65 M(+11.3%) | -$19.20 M(+0.9%) |
| Dec 2023 | -$19.03 M(+5.4%) | -$4.18 M(-9.1%) | -$19.03 M(-0.5%) |
| Sept 2023 | - | -$4.60 M(-20.5%) | -$19.13 M(+0.5%) |
| June 2023 | - | -$5.78 M(+29.0%) | -$19.03 M(+6.4%) |
| Mar 2023 | - | -$4.48 M(+4.6%) | -$17.89 M(-0.9%) |
| Dec 2022 | -$18.05 M(+22.1%) | -$4.28 M(-4.8%) | -$18.05 M(-4.1%) |
| Sept 2022 | - | -$4.49 M(-3.1%) | -$18.82 M(+0.1%) |
| June 2022 | - | -$4.64 M(-0.0%) | -$18.79 M(+11.9%) |
| Mar 2022 | - | -$4.64 M(-8.0%) | -$16.79 M(+13.5%) |
| Dec 2021 | -$14.79 M | -$5.04 M(+12.8%) | -$14.79 M(+35.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$4.47 M(+69.6%) | -$10.95 M(+53.1%) |
| June 2021 | - | -$2.64 M(-0.0%) | -$7.15 M(+44.8%) |
| Mar 2021 | - | -$2.64 M(+118.3%) | -$4.94 M(+73.4%) |
| Dec 2020 | -$2.85 M(-50.2%) | -$1.21 M(+80.1%) | -$2.85 M(+37.6%) |
| Sept 2020 | - | -$670.60 K(+58.9%) | -$2.07 M(-20.7%) |
| June 2020 | - | -$421.90 K(-22.9%) | -$2.61 M(-42.4%) |
| Mar 2020 | - | -$547.40 K(+27.3%) | -$4.53 M(-20.8%) |
| Dec 2019 | -$5.72 M(+165.9%) | -$430.00 K(-64.5%) | -$5.72 M(+8.1%) |
| Sept 2019 | - | -$1.21 M(-48.3%) | -$5.29 M(+29.7%) |
| June 2019 | - | -$2.34 M(+35.0%) | -$4.08 M(+135.0%) |
| Mar 2019 | - | -$1.74 M | -$1.74 M |
| Dec 2018 | -$2.15 M | - | - |
FAQ
- What is Inhibikase Therapeutics annual net profit?
- What is the all time high annual net income for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual net income year-on-year change?
- What is Inhibikase Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly net income year-on-year change?
- What is Inhibikase Therapeutics TTM net profit?
- What is the all time high TTM net income for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM net income year-on-year change?
What is Inhibikase Therapeutics annual net profit?
The current annual net income of IKT is -$19.03 M
What is the all time high annual net income for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual net profit is -$2.15 M
What is Inhibikase Therapeutics annual net income year-on-year change?
Over the past year, IKT annual net profit has changed by -$974.70 K (-5.40%)
What is Inhibikase Therapeutics quarterly net profit?
The current quarterly net income of IKT is -$5.78 M
What is the all time high quarterly net income for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly net profit is -$421.90 K
What is Inhibikase Therapeutics quarterly net income year-on-year change?
Over the past year, IKT quarterly net profit has changed by -$1.18 M (-25.74%)
What is Inhibikase Therapeutics TTM net profit?
The current TTM net income of IKT is -$19.57 M
What is the all time high TTM net income for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM net profit is -$1.74 M
What is Inhibikase Therapeutics TTM net income year-on-year change?
Over the past year, IKT TTM net profit has changed by -$435.10 K (-2.27%)